Lyell Immunopharma’s GCC-targeted CAR-T candidate LYL273 has cleared its manufacturing transfer to the company’s Bothell, Washington facility, but the Phase 1/2 trial in metastatic colorectal cancer is running behind its earlier schedule. The 8-K filed September 10, 2026 pairs the manufacturing milestone with a timeline revision, and for a program where manufacturing readiness was the stated gating factor, the two pieces of news carry opposite weight.
The 8-K confirms the technology transfer for LYL273 to Lyell’s LyFE Manufacturing Facility is complete. That matters because autologous cell therapy programs routinely stall at the point where academic-scale manufacturing protocols have to be rebuilt inside a commercial cGMP environment. Completing the transfer removes that specific bottleneck. The Phase 1 portion of the trial is designed to enroll up to roughly 95 patients, with a Phase 2 expansion of approximately 60 more at the recommended dose once that dose is identified. The revised timeline means that enrollment is now expected to progress on a later schedule than the company previously communicated, though the 8-K filing does not disclose a new target date in the truncated source body available.
The biology behind LYL273 is worth understanding here. Guanylyl cyclase C is expressed on colorectal epithelium and retained on the surface of most colorectal metastases, making it a cleaner target than the broadly expressed antigens that have driven toxicity in earlier solid-tumor CAR-T attempts. A published Phase 1 study of a dual GCC/CD19-targeted CAR-T in 15 relapsed or refractory metastatic colorectal cancer patients in China showed the antigen is actionable, though sample sizes at this stage of development make cross-trial comparisons unreliable. Metastatic colorectal cancer now has a growing menu of approved options, including adagrasib plus cetuximab for KRAS G12C-mutated disease, but patients who relapse after multiple lines of therapy face sharply narrower choices, which is where LYL273 is aimed.
The practical consequence for trial watchers is straightforward: manufacturing is no longer the constraint, and the program now depends on enrollment pace and dose-finding at sites that can handle autologous cell therapy logistics. The number to track is when Lyell reports its first safety and feasibility data from the Bothell-manufactured product, since that readout will determine whether the manufacturing transfer preserved the cell product characteristics established during earlier development.
Source link: https://www.sec.gov/Archives/edgar/data/1806952/000119312526387890/d278670d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
